ED Coding & Reimbursement Alert - 2003 Issue 26
Medicare Rx: FINANCIAL ANALYSTS: DRUG-ONLY PLANS A NO-GO
Subscribe or sign in to view the full article.
Article Overview
This brief policy article covers a Washington discussion of proposed Medicare prescription-drug legislation and the views of financial analysts on whether private drug-only plans could realistically participate. It is relevant to readers tracking Medicare policy, pharmacy benefit management, and health plan market structure, especially those interested in how analysts assess capital, risk, and insurer participation in new program models.
Why This Topic Matters
It provides a snapshot of expert commentary on a proposed Medicare drug benefit structure and the business feasibility of the entities expected to participate.
What You Will Learn
- What the article says about proposed Medicare prescription-drug plan structures
- How financial analysts viewed private drug-only plan participation
- Why capital reserves and risk assumptions were central to the discussion
- What role pharmacy benefit managers and health plans were expected to play
Who Should Read This
- Health policy analysts
- Medicare policy researchers
- Managed care professionals
- Pharmacy benefit management stakeholders
- Healthcare business and finance readers
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com